Literature DB >> 23073673

[Diagnosis and treatment of esophageal cancer].

R Kiesslich1, M Möhler, T Hansen, P R Galle, H Lang, I Gockel.   

Abstract

The prognosis for patients with advanced esophageal cancer is poor. Proper risk assessment and knowledge of tumor biology may facilitate early diagnosis of adenocarcinomas and squamous cell cancer of the esophagus. New endoscopic techniques are available (e.g., (virtual) chromoendoscopy, autofluorescence, and endomicroscopy) for the early detection of cancer. Endoscopic therapy with complete resection of mucosal cancers offers long-term survival.En bloc resection combined with the removal of locoregional lymph nodes is the surgical option of choice for locally advanced cancer. In this respect, minimally invasive surgery offers the patient numerous advantages. Multimodal therapy results in better outcome for defined cancer stages and includes surgery, chemotherapy and chemoradiation. Multimodal treatment should always be individualized and requires cooperation of all subspecialties (tumor board conference). New chemotherapeutic strategies may offer improved survival but may also include new side effects. Patients with inoperable esophageal cancer also benefit from multimodal treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23073673     DOI: 10.1007/s00108-012-3128-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  34 in total

1.  Total three-stage oesophagectomy for cancer of the oesophagus.

Authors:  K C McKeown
Journal:  Br J Surg       Date:  1976-04       Impact factor: 6.939

Review 2.  Endosonographic staging of upper intestinal malignancy.

Authors:  M Polkowski
Journal:  Best Pract Res Clin Gastroenterol       Date:  2009       Impact factor: 3.043

3.  Minimally invasive versus open esophagectomy: meta-analysis of outcomes.

Authors:  George Sgourakis; Ines Gockel; Arnold Radtke; Thomas J Musholt; Stephan Timm; Andreas Rink; Achilleas Tsiamis; Constantine Karaliotas; Hauke Lang
Journal:  Dig Dis Sci       Date:  2010-02-26       Impact factor: 3.199

4.  Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Authors:  Peter C Thuss-Patience; Albrecht Kretzschmar; Dmitry Bichev; Tillman Deist; Axel Hinke; Kirstin Breithaupt; Yasemin Dogan; Bernhard Gebauer; Guido Schumacher; Peter Reichardt
Journal:  Eur J Cancer       Date:  2011-10       Impact factor: 9.162

Review 5.  Confocal laser endomicroscopy in gastrointestinal diseases.

Authors:  Martin Goetz; Alastair Watson; Ralf Kiesslich
Journal:  J Biophotonics       Date:  2011-05-13       Impact factor: 3.207

6.  Limited resection for early adenocarcinoma in Barrett's esophagus.

Authors:  H J Stein; M Feith; J Mueller; M Werner; J R Siewert
Journal:  Ann Surg       Date:  2000-12       Impact factor: 12.969

7.  Incidence of adenocarcinoma among patients with Barrett's esophagus.

Authors:  Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

8.  Radiofrequency ablation in Barrett's esophagus with dysplasia.

Authors:  Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

9.  Minimally invasive esophagectomy: outcomes in 222 patients.

Authors:  James D Luketich; Miguel Alvelo-Rivera; Percival O Buenaventura; Neil A Christie; James S McCaughan; Virginia R Litle; Philip R Schauer; John M Close; Hiran C Fernando
Journal:  Ann Surg       Date:  2003-10       Impact factor: 12.969

10.  Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.

Authors:  S Lorenzen; T Schuster; R Porschen; S-E Al-Batran; R Hofheinz; P Thuss-Patience; M Moehler; P Grabowski; D Arnold; T Greten; L Müller; N Röthling; C Peschel; R Langer; F Lordick
Journal:  Ann Oncol       Date:  2009-06-23       Impact factor: 32.976

View more
  1 in total

1.  [Minimally invasive abdominothoracic esophagus resection by transoral esophagogastrostomy: interdisciplinary challenge].

Authors:  I Gockel; M Paschold; H Lang; F Heid
Journal:  Anaesthesist       Date:  2013-10       Impact factor: 1.041

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.